A Sea Change in Motion Sickness Therapy: Vanda Pharmaceuticals' Tradipitant Shows Promising Data in Real-world Test

  • Vanda Pharmaceuticals Inc VNDA announced the results from its Phase 3 study of tradipitant in motion sickness, confirming the previously reported results demonstrating that tradipitant effectively prevents vomiting associated with motion sickness
  • The Phase 3 study was conducted in real-world conditions on boats in the coastal waters of the U.S.
  • Also Read: Court Favors Vanda In Case Against FDA Over Detail Disclosure Of Rejection Of Sleep Disorder Drug.
  • In the Motion Syros study, 365 participants embarked on boat trips under varied sea conditions and received tradipitant 170 mg, tradipitant 85 mg, or placebo. 
  • Study participants had a prior history of motion sickness and were distributed across thirty-four boat trips between November 2021-April 2023. 
  • 170 mg and 85 mg tradipitant doses were superior to placebo in preventing vomiting, with only 18.3% and 19.5% of participants experiencing vomiting on tradipitant 170 mg and 85 mg, respectively, compared to 44.3% of participants on placebo.
  • The FDA has not approved a new medication for motion sickness in over forty years since scopolamine, a transdermal patch placed behind the ear, was approved in 1979.
  • Price Action: VNDA shares are down 1.39% at $6.03 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!